Amgen to obtain ChemoCentryx for nearly $4 billion
Click Here to Manage Email Alerts
Amgen announced that it will acquire ChemoCentryx Inc. for $52 per share in cash, amounting to nearly $4 billion in cash, in the fourth quarter of 2022.
In addition to obtaining ChemoCentryx, a biopharmaceutical company that aims to treat autoimmune diseases, inflammatory disorders and cancer with orally administered therapeutics, Amgen will also receive Tavneos (avacopan) in the deal.
“The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with Tavneos, a transformative, first-in-class treatment for antineutrophil cytoplasmic autoantibody-associated vasculitis,” Robert A. Bradway, chairperson and CEO at Amgen, said in the release.
ChemoCentryx has also been developing three early stage drug candidates that focus on chemoattractant receptors in other inflammatory diseases and an oral checkpoint inhibitor for cancer, all of which are intended to be included in the transaction.
“A fierce commitment to improving human lives is the bond that unites Amgen and ChemoCentryx today,” Thomas J. Schall, PhD, president and CEO of ChemoCentryx, said in the release. “Last year, after 25 years of proud history, we at [ChemoCentryx Inc.] CCXI delivered on our founding promise with the approval of Tavneos for patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. It is an honor to now join Amgen’s great mission, and together begin a bright new era bringing landscape-shaping medicines like Tavneos to those who will benefit most.”
Click Here to Manage Email Alerts